Today’s pharmaphorum podcast addresses the subject of speed – the velocity at which biopharma is bringing new therapies and medicines to market faster.
Going against the advice of its own advisors, the European Commission has said that PTC Therapeutics’ Translarna therapy for Duchenne muscular dystrophy (DMD) should stay
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.